The Hidden Cost Of Off-The-Shelf Media In Cell Therapy

By Asma Ayari, Ph.D.

It is easy to see why off-the-shelf media might seem like the most convenient and cost-effective solution for cell therapy development. But this approach often introduces costly downstream issues that compromise cell performance, delay regulatory approval, and force expensive revalidations during scale-up. In cell therapy, your media is more than just a consumable; it’s a strategic asset that impacts cell phenotype, expansion efficiency, and reproducibility. The right media strategy can reduce risk and accelerate your path to the clinic by ensuring scalability and regulatory readiness from the start.

Read this article to learn more about the hidden costs of using off-the-shelf media and how a proactive media strategy can save you time and money.